Details of the Drug Combination

General Information of Drug Combination (ID: DCFZS00)

Drug Combination Name
LJN452 Cenicriviroc
Indication
Disease Entry Status REF
Non-alcoholic Steatohepatitis (NASH) Phase 2 [1]
Component Drugs LJN452   DM3XRUH Cenicriviroc   DM4V8WF
N.A. Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of LJN452
Disease Entry ICD 11 Status REF
Primary biliary cholangitis DB96.1 Phase 2 [2]
LJN452 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Farnesoid X-activated receptor (FXR) TTS4UGC NR1H4_HUMAN Agonist [5]
------------------------------------------------------------------------------------
Indication(s) of Cenicriviroc
Disease Entry ICD 11 Status REF
Human immunodeficiency virus infection 1C62 Phase 2 [3]
Human immunodeficiency virus-1 infection 1C62 Phase 2 [4]
Cenicriviroc Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
C-C chemokine receptor type 5 (CCR5) TT2CEJG CCR5_HUMAN Modulator [6]
C-C chemokine receptor type 2 (CCR2) TTFZYTO CCR2_HUMAN Antagonist [4]
------------------------------------------------------------------------------------
Cenicriviroc Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [7]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [7]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03517540) Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 801).
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 FXR modulators for enterohepatic and metabolic diseases.Expert Opin Ther Pat. 2018 Nov;28(11):765-782.
6 The dual CCR5 and CCR2 inhibitor cenicriviroc does not redistribute HIV into extracellular space: implications for plasma viral load and intracellular DNA decline. J Antimicrob Chemother. 2015 Mar;70(3):750-6.
7 Pharmacokinetics, safety, and CCR2/CCR5 antagonist activity of cenicriviroc in participants with mild or moderate hepatic impairment. Clin Transl Sci. 2016 Jun;9(3):139-48.